Second-Line Treatment of Lower-Risk MDS With Symptomatic Ane

Continuing their discussion on the first patient profile, the expert panel focuses on the second-line treatment of patients with lower-risk MDS and symptomatic anemia.

Related Keywords

, Evolving Treatment Landscape , Myelodysplastic Syndromes , Line Treatment , Mds , Patient Case , Patient Profile , Anemia , Sf3b1 , Luspatercept , Mds Treatment , Myelodysplastic Syndromes Treatment , Repo , Medalist Trial ,